---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-022403"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:36:56.821915+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Monopar enrolls first patient in Phase 1 trial of MNPR-101-Zr radiopharmaceutical

## Summary
- First-in-human Phase 1 dosimetry and imaging trial of MNPR-101-Zr, a uPAR-targeting radiopharmaceutical.
- Up to 12 patients with advanced cancers will be enrolled in the study.
- Trial led by Professor Rodney Hicks at the Melbourne Theranostic Innovation Centre.
- First human study of a radiolabeled monoclonal antibody targeting uPAR.

## SEC filing metadata
- accession: 0001437749-24-022403
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924022403/0001437749-24-022403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924022403/mnpr20240708_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-022403
- JSON: https://secwatch.observer/filing/0001437749-24-022403.json
- Plain text: https://secwatch.observer/filing/0001437749-24-022403.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.